Literature DB >> 35596075

Lilly's tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics.

Asher Mullard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35596075     DOI： 10.1038/d41573-022-00094-2

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   112.288


× No keyword cloud information.
  1 in total

Review 1.  Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.

Authors:  Vivek P Chavda; Jinal Ajabiya; Divya Teli; Joanna Bojarska; Vasso Apostolopoulos
Journal:  Molecules       Date:  2022-07-05       Impact factor: 4.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.